Corporate profile 2014

Corporate Profile 2014

YOUR STRATEGIC PARTNER FOR R+D+i AND PRODUCT SOLUTIONS OUR COMPANY OFFER DIFFERENT SOLUTIONS, INNOVATIVE, ADVANCED, IMAGINATIVE AND AMAZING FOR A NUMBER OF PROFESSIONAL, INDUSTRIAL OR ARTISAN SECTORS WITHIN FIELDS FROM FOOD & NUTRIOTION TO HUMAN AND/OR ANIMAL HEALTH, PHARMACEUTICS, BIOTECHNOLOGY, MOLECULAR DEVELOPMENT, DISCOVERY, AND MANY OTHERS ON AN IMMPRESSIVE PORTFOLIO OF OVER 150.000 REFERENCES. FROM CLASSIC RAW MATERIALS TO THE MOST ADVANCED AND NEWLY CREATED OR DISCOVERED PRODUCTS, OUR COMPOUNDS AND FORMULAS ARE READY TO SOLVE ANY PROBLEM OR SITUATION PLANTED WITHIN THE INDUSTRY FIELDS WHERE OUR CUSTOMERS, FRIENDS, COOPERATORS AND THE GENERAL SECTOR MAY DEMAND OR NEED. WE ARE CONCERNED WITH A NON-STOP INNOVATION POLICY TO OFFER TO YOU OUR BEST EVERY DAY AND THUS FAR OPPORTUNITTIES TO GROW TOGETHER WITH EACH DEVELOPMENT AND MILESTONE ATTAINED, ALWAYS WITHIN OUR MISION, VISION AND VALUES AS COMPANY FAIRLY PRESENT IN A RADICAL HONESTY COMPROMISE.

This is why we are who we are and done what we are doing.

This is why we are ND Pharma & Biotech Co.

Creating Value. Delivering Sustainable Growth As a company with global vocation, our commercial success depends exclusively on our ability to create innovative products and successful brands, giving access to such value to the entire world. Our growing strategy is marked by the challenging economic environment that we are facing around the globe. Despite this we were growing and progressing with our sustainable business strategy, making our products accessible virtually across all continents. We started from a one product company with two employees and tons of illusion and knowledge gathered during more than 25 years service within different fields and industry sectors into an innovative leader in science, materials, food, preservation, biopharmaceuticals, specialty chemicals, rare molecules and a number of fields by recognizing ways to build value and drive sustainable growth. Every year is a new challenge for us, in terms of managing risk taking decisive actions to mitigate economic impact, reducing complexity, cutting costs and letting our clients to generate savings.

We move thru a key value driver to make life and world better, from our strategically integrated portfolio, our open innovation calendars for growth, and putting our capital to operate more efficiently for us and our clients, accelerating ND Pharma & Biotech performance to reach all and one of our objectives and goals planned as well as our customers’ ones.

The Company ND Pharma & Biotech Co. was founded in 2009 and was incorporated in England and Wales in 2012 as a company limited by shares with a total shares amount of 210.000.100 of 1 GBP each one.

ND Pharma & Biotech Company Limited brings world-class science and products to the global marketplace in the form of innovative products, materials and services. The company believes that by collaborating with customers, governments, non-gov-organizations and thought leaders it can help find solutions to such global challenges as providing solutions for certain medical and health conditions society has to deal now, improvement of pharmaceuticals, Biochemicals, API´s, intermediates, reagents, and rare chemicals, trading products, fine and non poisonous ingredients, and many more products, in order to let manufacturers and industry sectors to elaborate healthy foods, beverages, medicines, and many other products suitable for health protection and wellness promotion for people everywhere, decreasing dependence on toxic chemicals and protecting life and the environment.

Our system of collaborative and cooperative work let us to count a total worldwide employment at December 31, of 53 direct and 300 (mostly indirect) people. The company has operations in a number of countries worldwide and about 60 percent of consolidated net sales are made to customers within the EU actually.

Subsidiaries and affiliates of ND Pharma & Biotech Co., conduct manufacturing, production or selling activities and some are distributors of products manufactured by the company. As a science and technology based company, ND Pharma & Biotech competes on a variety of factors such as product quality and performance or specifications, continuity of supply, price, customer service and breadth of product line, depending on the characteristics of the particular market involved and the product or service provided.

Most products are marketed primarily through the company's sales force, although in some regions, more emphasis is placed on sales through distributors.

The company utilizes numerous suppliers as well as internal sources to supply a wide range of raw materials, energy, supplies, services and equipment. To ensure availability, the company maintains multiple sources for many raw materials.

Large volume purchases are generally procured under competitively priced supply contracts.

Our Developments

Our Business ND Pharma & Biotech Company Limited. (ND Pharma, the Comapny, we or us), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical needs and operate and conduct businesses many other fields and sectors, most of them related to human health as food, nutrition, biosciences, neurosciences, etc.

In the Bio-Pharmaceutical sector, as example, and with each new discovery and experimental drug candidate, we seek to improve the care of patients suffering from life-threatening diseases around the world.

Headquartered in the U.K., we have operations in North and Latin America, Europe and Asia. We continue to add to our existing portfolio of products through our internal discovery and clinical development programs and through a product acquisition and in-licensing strategy.

During our short existence we have launched a number of products, technologies and brands that are revolutionizing certain specific industry processes and fields from health to nutrition or crop protection.

Business Segments The company's reportable segments are R+D+i, Communications, Industrial Biosciences, Food, Nutrition & Health, Performance Chemicals, Performance Materials, Safety & Protection, Bio-Pharmaceuticals, Pharmacy, Health & Medicine, Public Health, Consumer Brands, and Innovation Management.

The company includes certain embryonic businesses not included in the reportable segments, such as pre-commercial programs, and nonaligned businesses as Stem Cell Technology, and some start-up projects non-consolidated.

As the world's population grows and the middle class expands, the need for crops for animal feed, food, biofuels and industrial uses continues to increase. The business competes with other fields and sectors as it usually happens within biotechnology companies.

Backlog In general, the company does not manufacture its products against a backlog of orders and does not consider backlog to be a significant indicator of the level of future sales activity. Production and inventory levels are based on the level of incoming orders as well as projections of future demand. Therefore, the company believes that backlog information is not material to understanding its overall business and should not be considered a reliable indicator of the company's ability to achieve any particular level of revenue or financial performance.

Intellectual Property ND Pharma & Biotech believes that its intellectual property estate provides it with an important competitive advantage. It has an established global network of attorneys, agents and experts as well as branding, advertising and licensing professionals, to procure, maintain, protect, enhance and gain value from this estate.

The company has access to a large patent portfolio, both owned and licensed.

These definite-lived patents cover many products, processes and product uses.

These patents protect many aspects of the company's significant research programs and the goods and services it sells. The actual protection afforded by these patents varies from country to country and depends upon the scope of coverage of each individual patent as well as the availability of legal remedies in each country. ND Pharma & Biotech Co, has accounted practically the total amount of its statement of capital on the estimated value of IP rights and other applicable rights under its patents and licenses, as well as the products made and sold under them, that are important to the company as a whole, and to varying degrees, important to each reportable segment. The estimated value of total portfolio is situated around the 750 Mâ‚Ź, at the end of December 2013.

Trade secrets are an important element of the company's intellectual property. Many of the processes used to make ND Pharma & Biotech products are kept as trade secrets which, from time to time, may be licensed to third parties. ND Pharma & Biotech vigilantly protects all of its intellectual property including its trade secrets.

When the Company discovers that its trade secrets have been unlawfully taken, it reports the matter to governmental authorities for investigation and potential criminal action, as appropriate. In addition, the company takes measures to mitigate any potential impact, which may include civil actions seeking redress, restitution and/or damages based on loss to the company and/or unjust enrichment.

Ownership of and access to intellectual property rights, particularly those relating to biotechnology and innovations in food, nutrition, ingredient´s health, etc. , will continue to be important to ND Pharma & Biotech and its competitors. The environment in which Company competes is characterized by the use among competitors of intellectual property rights, including patent lawsuits, to gain advantage in commercial markets. In support of its business, ND Pharma & Biotech Co. continues to build a large collection of intellectual property rights related to biotechnology and other fields and sectors where the company operates and to license technology from others, including competitors. ND Pharma & Biotech Co., endeavors to obtain such licenses on commercially reasonable terms.

Research and Development The company conducts research at either dedicated research facilities or manufacturing plants. There are eleven major research locations in the U.S. & Canada, The United Kingdom, Spain and Asia (Japan). Reflecting the company's global interests, research locations are located in the Asia Pacific region, in Europe, Middle East and Africa (EMEA) region and one major location is located in Latin America.

Research is the main activity of our Company, that is purported thru ND Innovation (a wholly owned subsidiary of ND Pharma & Biotech Co.) The company has a number of unique trademarks for its products and services and holds also a number of registrations for these trademarks worldwide.

Ownership rights in trademarks do not expire if the trademarks are continued in use and properly protected. The company has many trademarks that have significant recognition at the consumer retail level and/or business to business level.

The objectives of the company's research and development programs are to create new technologies, processes and business opportunities in relevant fields, as well as to improve existing products and processes. Each segment of the company funds research and development activities that support its business mission.

The company is expanding its offerings addressing safety, environment, energy and climate challenges in the global marketplace by developing and commercializing renewable, bio-based materials; advanced biofuels; energyefficient technologies; enhanced safety and protection products; and alternative energy products and technologies as well as real innovations in about all sectors and fields where the company is operating actually.

The goals are tied directly to business growth, including increasing food production, increasing renewable sources for energy and raw materials, and providing greater safety and protection for people and the environment. All research and development activities are administered by senior research and development management to ensure consistency with the business and corporate strategy so therefore the future of the company is not dependent upon the outcome of any single research program.

The senior research management is leaded by the Chief Scientific Officer, that is also a member of the Board.

Competition Our marketed products target a number of areas. There are many commercially available products from ND Pharma & Biotech Co,, as well as many brands and third party´s products improved thru our innovations or incorporating such.

Many companies and institutions are making substantial investments in developing additional products to re-shape, improve, totally change and re-positioning their own brands and products thanks to our developments.

Our products compete with other available products based primarily on efficacy; safety; tolerability; acceptance by consumers, industry, producers, processors, and many others; ease of patient compliance; patent protection; ease of use; price; distribution and marketing.

We developed an strategic competition based on some of our unrivalled products and brands.

Collaborative Relationships As part of our business strategy, we establish collaborations with other companies, universities and medical research institutions to assist in the clinical development and/or commercialization of certain of our products and product candidates and to provide support for our research programs.

We also evaluate opportunities for acquiring products or rights to products and technologies that are complementary to our business from other companies, universities and medical research institutions, technological centers and other research-based companies.

Commercial Collaborations Although we currently have a number of collaborations with corporate partners that govern the manufacture, sale, distribution and/or marketing of our products in various territories worldwide, we entered in some quite interesting commercial collaborations with those that are most significant to us from a financial statement perspective and where significant ongoing collaboration activity exists.

Some of our existing partners are listed within our websites and commercial micro-sites that can be accessed thru www.ndpharmabiotech.com.

Patent Protection and Certain Challenges relative to medicines, health products, and related technologies Patents and other proprietary rights are very important to our business. If we have a properly drafted and enforceable patent, it can be more difficult for our competitors to use our technology to create competitive products and more difficult for our competitors to obtain a patent that prevents us from using technology we create.

As part of our business strategy, we actively seek patent protection both in the United States and internationally and file additional patent applications, when appropriate, to cover improvements in our compounds, products and technology.

We also rely on trade secrets, internal know-how, technological innovations and agreements with third parties to develop, maintain and protect our competitive position. Our ability to be competitive will depend on the success of this strategy.

Patents covering the active pharmaceutical ingredients of some of our developments are held by third parties. We acquired exclusive rights to these patents in the agreements we have with these parties.

Patents do not cover the total developments we´ve made and those we are discovering. When this happens we cover formulations of this compounds and also protect such formulations through trade secrets.

We may obtain patents for certain products many years before marketing approval is obtained for those products.

Because patents have a limited life, which may begin to run prior to the commercial sale of the related product, the commercial value of the patent may be limited.

However, we may be able to apply for patent term extensions and other many forms of IP rights protection as supplementary certificates or supplementary protection certificates on many of our products that have been granted in the United States and in a number of European countries, compensating in part for delays in obtaining marketing approvals.

Similar patent term extensions may be available for other products that we are developing, but we cannot be certain we will obtain them in some countries.

It is also very important that we do not infringe the valid patents or proprietary rights of others and that we do not violate the agreements that grant proprietary rights to us.

If we do infringe valid patents or violate these agreements, we may be prevented from commercializing products or from using the processes covered by those patents or agreements, or may be required to obtain a license from third parties to allow us to use their technology.

We may be unable to obtain alternative technologies or any required license on reasonable terms or at all.

If we fail to obtain these licenses or alternative technologies, we may be unable to develop or commercialize some or all of our products. We own patents that claim for certain molecules as a chemical entity (CE´s) and its metabolites.

However, the existence of issued patents does not guarantee our right to practice the patented technology and/or commercialize the patented product.

Third parties may have or obtain rights to patents which they may claim could be used to prevent or attempt to prevent us from commercializing the patented product candidates obtained from the acquisition.

We are aware of patents and patent applications owned by other parties that might be alleged to cover the use of certain products that were developed by us, sometimes prior to Company formation and regularization, protection and/or reconciliation with our own developments, molecules, chemical entities and discoveries.

If these other parties are successful in obtaining valid and enforceable patents, and establishing our infringement of those patents, we could be prevented from selling some of those molecules unless we were able to obtain a license under such patents. If any license is needed it may not be available on commercially reasonable terms or at all.

ND Pharma & Biotech (as successor to PharmaCot Health Technologies) is a party to a collaboration agreement with some existing companies as IBT Chicago or the most recent OLT, Denver.

Because patent applications are confidential for a period of time until a patent is issued, we may not know if our competitors have filed patent applications for technology covered by our pending applications or if we were the first to invent or first to file an application directed toward the technology that is the subject of our patent applications.

Competitors may have filed patent applications or received patents and may obtain additional patents and proprietary rights that block or compete with our products. In addition, if competitors file patent applications covering our technology, we may have to participate in interference/derivation proceedings or litigation to determine the right to a patent. Litigation and interference/derivation proceedings are unpredictable and expensive, such that, even if we are ultimately successful, our results of operations may be adversely affected by such events.

Patents relating to pharmaceutical, biopharmaceutical and biotechnology products, compounds and processes such as those that cover our existing compounds, products and processes and those that we will likely file in the future, do not always provide complete or adequate protection.

Future litigation or re-examination proceedings regarding the enforcement or validity of our existing patents or any future patents could invalidate our patents or substantially reduce their protection. From time to time, certain individuals or entities may challenge our patents, what constitutes also a risk factor to our company.

Manufacturing and Raw Materials Our manufacturing strategy is to contract with third parties to manufacture the majority of our active pharmaceutical ingredients and solid dose products. We also rely on our corporate partners to manufacture certain of our products.

These include food & nutrition formulas, compounds, etc. Additionally, we own or lease manufacturing facilities where we manufacture certain products and active pharmaceutical ingredients for clinical and commercial uses as well as a pilot plant where we manufacture the vast majority of our pre-packed/readyto-go products and samples under higher standards.

Manufacturing of our Products We contract with third parties to manufacture certain products for clinical and commercial purposes including some of our trademarks from PreserFood TM to Noopeptil TM. We use multiple third-party contract manufacturers to manufacture some of our API´s. We rely on a single third-party manufacturer to manufacture some of our StarBranded® products and some others under the “SOL” TERMINATION AS SUCRASOL®, ASPARSOL®, etc.

We are the exclusive manufacturer of the active pharmaceutical ingredients that we sell under our SpeciBrands® within a certified premises throughout a subsidiary company that is fully operated by ND Pharma & Biotech.

We also rely on third-party contract manufacturers to tablet or capsulate products.

We also have manufacturing agreements with many of our corporate partners.

For our future products, we continue to develop additional manufacturing capabilities and establish additional third-party suppliers to manufacture sufficient quantities of our product candidates to undertake clinical trials and to manufacture sufficient quantities of any product that is approved for commercial sale. If we are unable to develop manufacturing capabilities internally or contract for large scale manufacturing with third parties on acceptable terms for our future products, our ability to conduct large scale clinical trials and meet customer demand for commercial products will be adversely affected.

Third-party Manufacturers Our third-party manufacturers and our corporate partners are independent entities who are subject to their own unique operational and financial risks which are out of our control.

If we or any of our third-party manufacturers or our corporate partners fail to perform as required, this could impair our ability to deliver our products on a timely basis or receive royalties or cause delays in our clinical trials and applications for regulatory approval.

To the extent these risks materialize and affect their performance obligations to us, our financial results may be adversely affected.

We believe the technology we use to manufacture our products is proprietary. For products manufactured by our third-party contract manufacturers, we have disclosed all necessary aspects of this technology to enable them to manufacture the products for us.

We have agreements with these third-party manufacturers that are intended to restrict these manufacturers from using or revealing this technology, but we cannot be certain that these third-party manufacturers will comply with these restrictions. In addition, these third-party manufacturers could develop their own technology related to the work they perform for us that we may need to manufacture our products.

We could be required to enter into additional agreements with these third-party manufacturers if we want to use that technology ourselves or allow another manufacturer to use that technology. The third-party manufacturer could refuse to allow us to use their technology or could demand terms to use their technology that are not acceptable to us.

Regulation of Manufacturing Process The manufacturing process for pharmaceutical products is highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations.

We, our third-party manufacturers and our corporate partners are subject to current Good Manufacturing Practices, which are extensive regulations governing manufacturing processes, stability testing, record keeping and quality standards as defined by the FDA and the EMA. and other regulatory bodies in different parts of the World.

Similar regulations are in effect in other fields and sectors as Food & Nutrition, etc.

The company has top compliance standards and such exigencies apply also for other operators and entities working for us.

Our manufacturing operations are subject to routine inspections by regulatory agencies that we are conformed and became resolved without any incidences.

Access to Supplies and Materials We need access to certain supplies and products to manufacture our products. If delivery of material from our suppliers were interrupted for any reason or if we are unable to purchase sufficient quantities of raw materials used to manufacture our products, we may be unable to ship certain of our products for commercial supply or to supply our product candidates in development for clinical trials.

Seasonal Operations and Backlog Our worldwide product sales do not reflect any significant degree of seasonality.

However, our royalty revenues, which represented approximately 3% of our total revenues in 2013 are affected by seasonality. For the most part, we operate in markets characterized by short lead times and the absence of significant backlogs. We do not believe that backlog information is material to our business as a whole, as stated previously within this document.

Government Regulation Our operations and activities are subject to extensive regulation by numerous government authorities in the United States and other countries. In the United States, drugs are subject to rigorous FDA regulation. The Federal Food, Drug and Cosmetic Act and other federal and state statutes and regulations govern the testing, manufacture, safety, efficacy, labeling, storage, record keeping, approval, advertising and promotion of our products. As a result of these regulations, product development and product approval processes are very expensive and time consuming. In Europe and other countries we comply with all sets of existing regulations and compilations of norms and laws. Our Regulation and Legal Departments work extensively to accomplish this situations and to let our customers to have the trust, confidence and tranquility of being a hundred percent within the legal stipulations of every country of operations and control.

Research + Development + Innovation We vigorously invest in research, development and innovation to discover and develop new products and eventually, new treatments that meet the needs of specialty doctors and their patients.

Our company try to develop world-class research + development + innovation (R&D+i) programs that embodies our efforts to bring the best of science to medicine and therefore to life, including some new developments within the nutrition science, food, feed and certain industrial sectors.

Scientists and researchers work closely with specialists within their respective areas, to transform novel compounds into new therapeutics and products that help improve quality of life. This philosophy is consistent with our motto; Making Life Better

Our commitment to R&D has been evident since our inception, when we began pioneering new treatments to help preserve certain organic and body functions including neurological functions as memory and cognoscitive abilities. Since then, our investment in R&D+i has progressively increased to a level that is considered best in class for the industry, and we have followed our products into new specialty areas.

Our R&D+i programs today are focused in many areas ranging from diabetes and nutrition to surgical innovations. Currently, we are investigating a rich arsenal of potential new treatments for chronic migraine, debilitating neurological conditions, eye disease, and stem cell transplantation, among other conditions and fields.

Significant progress in these areas is expected to be made over the next decade advances in which we look forward playing a prominent role.

Since founding, our company retains the ability to listen and to learn - from our customers, and from each other - has been a cornerstone of our success. ND Pharma & Biotech´s R&D+i culture reflects this, providing an open forum for our and other scientists to share ideas, collaborate on projects, and gain access to the latest research.

Access to world-class technology combined with intellectual stimulation results in a dynamic environment where scientists are excited about the work they do and committed to pushing the boundaries of what is possible.

Our R&D+i organization is structured into integrated teams that focus on discovery for different targets. This unique architecture affords many benefits. Scientists normally confined to specific tracks have the opportunity to be involved in the full life-cycle of development, from early-stage exploration to human testing, for a much broader perspective. Additionally, meticulous research is streamlined with highly efficient project and information management, which can save years and millions of dollars from the overall cost of drug development.

Most of our discovery and development programs are initiated internally, which sets us apart from many other health care companies. Simultaneously, we explore new market opportunities and search for partnerships to develop superior technologies that are complementary to our own business model.

In short, at our company, there will be only one way in which we view the purpose of science and innovation - to identify those needs in health care and certain industrial sectors that are unsolved and commit to finding solutions through a meaningful R&D+i investment that fuels future growth. This is our unwavering commitment.

Our Commitment with/for Excellence in Research & Development.

For every new treatment/product that comes to market, hundreds of important discoveries are made along the way that contribute to science, medicine, health and technology. For these contributions and many others, ND Pharma & Biotech provides several opportunities for our scientists to be recognized and rewarded for excellent work in their respective fields and broadly.

Research at our company is ongoing, and with some of the best talent in the health care industry, our scientists regularly publish key findings in peer-reviewed medical journals and other scientific publications both indexed or not. Company also attends key medical and industry meetings throughout the year, where our scientists present their published findings and research in front of their peers.

We are grateful to those members on and related to any of our teams who have demonstrated their commitment to science, technology, healthcare and medicine.

Their commitment, intellect, and innovative thinking have the power to advance clinical discoveries and product development and improve the way we and our beloved ones are living.

Our scientists, team leader and project managers are selected and distinguished members of different well-known, well-reputed scientific, medical and research organizations, professional bodies and institutions, maintaining membership and good standing with all relevant societies and up-to-date information, tools and means.

Our Publications

S TO E T U IA RO NEWHT ANAEM FIG

D TIRE

IRED ING T

?

E OF B

N

rmula

AVIVA

B rma & D Pha

iotech

Fo grated

´s Inte

iency

n Defic

nd Iro Iron a

itions

Cond

CH BIOTE & A UICE HARM ND P FRUIT & J ION VAT INNO ND P HAR E

DELIV

RING

MA & THRO BIOTEC UG H

VALUE

ND P HARMA

&

B IOTECH

2013 FACT BOOK

H INN

OVATIO N

2013-2015

ND Pharma & Bio

tech OUR BRANDS YOUR SOLUTIONS ND PHARMA & BIOTECH

INDU

STRIA

L DIV

ND P ha

ISION

rma & Biotec h

A CO TURE TM PURE NA TIONS LU SUPERSO T REV A PRODUC

OLUTION

TECH RMA & BIO

PHA FROM ND

LOUR FUL EXPE RIEN CE

Excellence in Research For every new treatment that comes to market, hundreds of important discoveries are made along the way that contribute to science, medicine, and technology. For these contributions and many others, ND Pharma & Biotech provides several opportunities for our scientists to be recognized and rewarded for excellent work. Research at ND Pharma & Biotech is ongoing, and with some of the best talent in the health care industry, our scientists and research cooperators regularly publish key findings in peerreviewed medical and scientific journals. We also attends key medical and industry meetings throughout the year, where our scientists present their published findings and research in front of their peers.

We are grateful to those members on the ND Science team who have demonstrated their commitment to science, technology, and medicine. Their commitment, intellect, and innovative thinking have the power to advance clinical discoveries and improve the way we live.

Corporate Research Agreements and collaborations While most of our discovery and development programs are developed internally making ND Pharma & Biotech quite unique in the industry - we are continuously looking for partnerships and superior technology that complement our business model.

Some of our current collaborations include: Exclusive licensing agreements with multi-purpose Research Centers and Universities Worldwide, including some of the most prominent in the fields. A multi-year alliance with Mayfield Clinic and major providers of Regenerative Research and Treatment in the Stem Cells sector.

Multiple lines of research opened within different private institutions worldwide where ND Pharma & Biotech participates within different collaborative ways.

Our new molecules laboratory develops and investigate within new molecule´s latest developments to give industry and professionals different levels of response and tools to fight against certain conditions and unmet medical and health illnesses from neurology to orthopedics, eye care to vascular disorders o addictions medicine.

Between those discoveries appear certain forms of plant-derived new molecules for the treatment of most aggressive conditions.

Agreements with major industry labs and research organizations to develop solutions for food and nutrition industry in order to achieve one of our motivational goals of removing toxic chemicals from food within the industry.

Â

ND PHARMA & BIOTECH is constantly seeking for partnerships and associations in everyone of the fields that we developed and where we conduct business. These partnerships and associations include academic institutions, research centers, other corporations and individuals.

Partnering is a key component of our business strategy, as we consider every possibility to develop and partner successful programs to pharmaceutical, biotechnology and medical device products, services, components and companies.

We welcome enquiries from other companies wishing to discuss any partnering opportunity with us.

In-Licensing is another source of business for us. We welcome contacts from academic institutions, inventors, researchers and other operators within the industry from Biotech, Pharma, or other related fields. Our prime filter criteria is based on a three step consideration initial process: • have strong intellectual property positions; • address significant unmet medical, health, food, nutrition, or analogue needs, and • have the potential to enter into development within 12 to 18 months after acquisition or licensing.

Working with corporate partners.

ND PHARMA & BIOTECH focuses in developing pioneering and novel products, drugs, and molecules in specialist areas, from food to pharma and therapy where there is a distinct lack of existing solutions, with emphasis in personalized medicine and novel therapies in the field of Regenerative Medicine, Stem Cell Advancement and other like nutrition.

Since our foundation, our research strategy has been to work closely to different "first line" institutions and operational centers that conduct investigation for us, under guidance and supervision of our clinical & scientific director´s team. These institutional cooperation enables us to access innovative research and cutting edge discovery with substantial added value and immediate application to the developments under a relatively optimized costs. ND Pharma & Biotech maintains exclusive tights to all the intellectual property assets generated under such cooperation agreement and the research and development conducted.

Our market strategy, specially referred to pharmaceutical and therapeutic industry is to license our assets to leading international corporations and/or other industry operators (nutrition, food, feed, etc.) that are interested in further development and commercialization of some molecules and/or drugs.

We offer distinctive solutions to a number of unmet clinical conditions, diseases and pathologies.

Our Products

AVIVA Iron and Iron Deficiency Conditions!

!

ND Pharma & Biotech ´s Integrated Formula!

GIVE%MORE%LIFE%AND%PROTECTION%TO%YOUR%JUICE,%MAKING%THEM%

KANGENJUICES

Important information about AVIVA TM

AVIVA TM 100% Natural Ingredient´s Formula. This is not a drug. It´s a nutritional supplement (OTC) prescription-free. In some cases and under specific conditions it may be recommended by your physician/doctor/nurse/ pharmacist/ dietitian/nutritional advisor, etc.. Statements regarding AVIVA TM has not been evaluated by any agency or regulator in the world. This product is based on research and discovery of alternative metabolic routes of iron metabolism and heme-building nutrient´s related necessities, so the product intake is a supply of such specific elements to the diet with a pretended higher level of bioavailability and easy digestion and metabolism with the help of certain natural absorption enhancers. Clinical tests and studies has shown a relative increase in Fe levels of consumers up to a 45% more than placebo and 25% more compared with iron and organic-iron preparations and supplements with a decrease curve in gastric discomfort and general reactions to iron intake. Results may vary from one individual to another by a number of uncertain and variable causes, age, sex, underlying conditions, other drug/treatments intake, diseases, nature of anemia, etc. If you may have any doubt about the use of AVIVATM please consult your family health practitioner or specialist. Or alternatively ask us regarding conditions that could be benefit with the use of this product or from the incorporation of AVIVA TM ingredients within their specific formulas.

NUTRICE Energy Secrets Unveiled

RibosolTM is an all natural ingredient and the best of all.

RibosolTM added to your products will help your consumers and clients worldwide to sustain their energy levels, recover faster and became ready sooner for everyday challenge that demands energy source along our busy daily lives.

Satisfy consumer´s thirst for new, nourishing and natural

+1.500&MILLION&OF&CONSUMERS&CAN&NOT&DRINK&JUICES&AND&& JUICE7DERIVED&BEVERAGES&

Consumers demand more than just juices. They want fun. Fluid nutrition. Beauty in a bottle. Naturally, of course. To help producers and bottlers to give natural answers to consumer´s demands we´ve created a deep research natural method, system and product to transform your regular product into premium and/or ultra-premium juice beverage, mixed one. Whether you may want a natural, high performance, nutritional formula, just to extend shelf life of juices or to prevent browning and acidity, or just to give your client´s the better off the best. Let us to help you to serve up satisfaction.

DUE TO

AcqualifeTM,JuiceBIO, 100%,NATURAL,MINERAL,INGREDIENT´S, FORMULA,FOR,HIGH,PERFORMANCE,JUICE, AND,JUICE,DERIVED,BEVERAGES,,

G.E.R.D.

info@ndpharmabiotech.com/ref.kangen% AcqualifeTMJuiceBIO, KANGEN® Trade Marks and logos are property of ND Pharma & Biotech Co

Safe and Clinically Proven Ingredient ND Pharma & Biotech

Get all the answers. %

Ask us about RibosolTM info@ndpharmabiotech.com

www.ndpharmabiotech.com,

RIBOSOLTM

www.ndpharmabiotech.com0

GASTRO ESOPHAGEAL REFLUX DISEASE AFFECTS WORLD POPULATION BETWEEN 11%-39% (Malaysia,

Mexico & Spain Top Ranked)*

*World Gastroenterology Organization

THE$NATURAL$POWERFUL$ENERGY$INGREDIENT$ON$DOSAGE$

Satisfy all consumers in a safe, natural and deliciously healthy way.

G.E.R.D. (Gastro Esophageal Reflux Disease, a medical and health condition that is affecting estimated to more than 1.500 millions of people worldwide, with impact within al ranges of age. This prevents those sufferers against the consumption of some juices and juicederived drinks. Thus far, such consumers are not able to gain healthy benefits of such drinks, and the producers are not reaching to a potential market that is constantly looking for another kind of drinks with a less acidic profile, spending money in some other products, less healthy and delicious. If you want to produce healthy juice and juice derived drinks and beverages, with alkaline profile, able to be consumed by all populations, we have the solution for all that questions.

AcqualifeTM JuiceBIO 100%$NATURAL$MINERAL$INGREDIENT´S$ FORMULA$FOR$HIGH$PERFORMANCE$JUICE$ AND$JUICE$DERIVED$BEVERAGES$$

You´ll Love Our Sugar ND Pharma Biotech

Get all the answers.

info@ndpharmabiotech.com/ref.kangen$ &

AcqualifeTMJuiceBIO, KANGEN® Trade Marks and logos are property of ND Pharma & Biotech Co.

& Making Life Better

www.ndpharmabiotech.com$

At0ND0Pharma0&0Biotech0we0are0concerned0about0you,0your0health,0your0nutri;on,0your0wellness0 as0well0as0the0health0of0all0those0that0ma>er0to0you,0your0beloved0ones.0We0know0that0actual0 diet0is0responsible0of0the0pandemic0problem0of0overweight0that0our0society0is0suffering0actually0 due0 to0 the0 overload0 of0 sugar0 and0 sugar0 derived0 products0 that0 we0 eat.,0 Sugar0 is0 a0 natural0

ND Pharma & Biotech creates SUGAR20TM to serve all sectors of industry andingredient0but0our0organism0needs0a0huge0amount0of0energy0and0metabolic0effort0to0process0it0 adequately.0 Every0 day,0 facing0 such0 overload0 of0 glucoses,0 we0 need0 to0 employ0 more0 deep0 and0 specifically those reluctant to renounce to the use of sugar within theirheavy0 work0 processes0 to0 eliminate0 it.0 As0 a0 consequence0 a0 number0 of0 secondary0 reac;ons0 and0 body0damages0appear0in0the0short,0mid0and0long0term.0 elaborated/manufactured products as ingredient.

ND Pharma & Biotech creates to serve all sectors of industry and specifically those reluctant to renounce to the use of sugar within their elaborated/manufactured products as ingredient.

is a complete sugar-based ingredient´s formula with a cuttingedge innovation process able to reduce naturally the amount and speed of sugar absorbed by organism up to a 50% less, reducing GI(Glycaemic Index) peaks and Insulin-Reactive response.

Every ingest of sugar will count just as much as 50% of total eaten, protecting thus far consumer´s health in a nutritional, safe and effective, natural tasty way.

0

We0fused0science0and0nutri;on0to0give0to0the0industry0a0formulated0compound0from0natural0and0

SUGAR20TM is a complete sugar-based ingredient´s formula with a cutting-mineral0ingredients0that0reduce0significantly0the0absorp;on0of0sugar0within0the0body0(diges;ve0 system)0up0to0a030%,0which0means0a0lesser0metabolic0reac;on0and0organic0effort,0so0therefore0 edge innovation process able to reduce naturally the amount and speed ofless0physiological0impact0and0thus0far0less0presumable0damages0secondary0to0such0overloads0of0 glucose0within,0specially0those0coming0from0the0inges;on0of0processed0foods0and0beverages,0and0 sugar absorbed by organism up to a 80% less, reducing GI(Glycaemic Index) peaksdiet0in0general.00 0 and Insulin-Reactive response.

As0us0about0this0innova;on0that0will0change0millions0of0lives.0

0

Every ingest of sugar will count just as much as 20% of total eaten, protectingAsk$us$about$$MONKÍ$TM$ thus far consumer´s health in a nutritional, safe and effective, natural tasty way.

Simple,(Fast(and(Easy( info@ndpharmabiotech.com11 1(Ref:%Sugar50%TM)1 1

www.ndpharmabiotech.com1

YOU´LL LOVE OUR SUGAR BECAUSE OUR SUGAR DO CARE FOR YOU Simple,(Fast(and(Easy( info@ndpharmabiotech.com11 1(Ref:%Sugar20%TM)1 1

www.ndpharmabiotech.com1

Business development and clients.

ND PHARMA & BIOTECH entered into some important and interesting corporate deals with major companies worldwide. So some of the "multi-billion dollar" corporations are now within our client´s list. Specifically within the food and nutrition industry we developed product innovation and license deals with the major producers of drinks, sodas, sport beverages and related industry sectors in the field, helping them to improve the quality, health and nutrition properties of their own products, both existing and other to appear. Other huge market corporations we work for include desert and ice-cream industry, infant nutrition labs and manufacturers, and large corporation of general foods.

ND PHARMA & BIOTECH also supply with active principles, transformation and refining of molecules and own developments to pharmaceutical industry including some of the "top ten" Pharma Corporations, with presence all around the world.

Operations.

ND PHARMA & BIOTECH operations are conducted worldwide. Since our PHARMA-BUSINESS DIVISION operates directly from our UK Headquarters, other related operational areas as FOOD and NUTRITION, conduct operations directly from different geographical areas.

Corporate Profile 2014